Isoeugenol

Isoeugenol

SCHEMBL3699102

C/C=C/c1ccc(O)c(OC)c1.Oc1ccccc1

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TYR P14679 1/20 0.81
▸ TTR P02766 2/20 0.64
▸ CA12 O43570 2/20 0.59
▸ CA4 P22748 2/20 0.59
▸ CA6 P23280 2/20 0.59
▸ CA5A P35218 2/20 0.59
▸ CA7 P43166 2/20 0.59
▸ CA9 Q16790 2/20 0.59
▸ CA14 Q9ULX7 2/20 0.59
▸ CA5B Q9Y2D0 2/20 0.59
▸ KDM4E B2RXH2 1/20 0.59
▸ CA1 P00915 1/20 0.59
▸ CA2 P00918 1/20 0.59
▸ CA3 P07451 1/20 0.59
▸ PKM P14618 1/20 0.59
▸ CSNK2A2 P19784 1/20 0.59
▸ SNCA P37840 1/20 0.59
▸ CSNK2B P67870 1/20 0.59
▸ CSNK2A1 P68400 1/20 0.59
▸ CSNK2A3 Q8NEV1 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cis/Trans-Isoeugenol SCHEMBL3699104 1.00 TYR (0.81) TYRTTRCA12CA4CA6
Isoeugenol SCHEMBL2686818 0.92 TYR (0.84) TYRTTRCA12CA4CA6
Cis/Trans-Isoeugenol SCHEMBL2686822 0.92 TYR (0.84) TYRTTRCA12CA4CA6
Isoeugenol SCHEMBL29369838 0.90 TYR (1.00) TYRTTRCA12CA4CA6
Isoeugenol SCHEMBL2463281 0.90 TYR (1.00) TYRTTRCA12CA4CA6
Isoeugenol SCHEMBL300766 0.90 TYR (1.00) TYRTTRCA12CA4CA6
Cis/Trans-Isoeugenol SCHEMBL57987 0.90 TYR (1.00) TYRTTRCA12CA4CA6
Cis/Trans-Isoeugenol SCHEMBL29361918 0.90 TYR (1.00) TYRTTRCA12CA4CA6
Isoeugenol SCHEMBL57986 0.90 TYR (1.00) TYRTTRCA12CA4CA6
Cis/Trans-Isoeugenol SCHEMBL2463283 0.90 TYR (1.00) TYRTTRCA12CA4CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013134220-A1 ELECTROCATALYTIC HYDROGENATION AND HYDRODEOXYGENATION OF OXYGENATED AND UNSATURATED ORGANIC COMPOUNDS BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 2013-09-12 — — WO disclosed
US-20120123155-A1 BIOCATALYST FOR CATALYTIC HYDROAMINATION BASF SE (DE) 2012-05-17 — — US disclosed
EP-1928992-A1 CONSUMER PRODUCTS HAVING VARYING ODORS Henkel AG & Co. KGaA (DE) 2008-06-11 — — EP disclosed
WO-2007028479-A1 CONSUMER PRODUCTS HAVING VARYING ODORS HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2007-03-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120123155-A1 BIOCATALYST FOR CATALYTIC HYDROAMINATION HDHD5, PAH, GRHPR TYR 27/4885TTR 1251/4885CA12 2675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback